FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313891762> ?p ?o ?g. }

• W4313891762 abstract "Background: The pharmacokinetic/pharmacodynamics (PK/PD) target derived from the hollow-fiber system model for linezolid for treatment of the multidrug-resistant tuberculosis (MDR-TB) requires clinical validation. Therefore, this study aimed to develop a population PK model for linezolid when administered as part of a standardized treatment regimen, to identify the PK/PD threshold associated with successful treatment outcomes and to evaluate currently recommended linezolid doses. Method: This prospective multi-center cohort study of participants with laboratory-confirmed MDR-TB was conducted in five TB designated hospitals. The population PK model for linezolid was built using nonlinear mixed-effects modeling using data from 168 participants. Boosted classification and regression tree analyses (CART) were used to identify the ratio of 0- to 24-h area under the concentration-time curve (AUC 0-24h ) to the minimal inhibitory concentration (MIC) threshold using the BACTEC MGIT 960 method associated with successful treatment outcome and validated in multivariate analysis using data from a different and prospective cohort of 159 participants with MDR-TB. Furthermore, based on the identified thresholds, the recommended doses were evaluated by the probability of target attainment (PTA) analysis. Result: Linezolid plasma concentrations (1008 samples) from 168 subjects treated with linezolid, were best described by a 2-compartment model with first-order absorption and elimination. An AUC 0–24h /MIC &gt; 125 was identified as a threshold for successful treatment outcome. Median time to sputum culture conversion between the group with AUC 0-24h /MIC above and below 125 was 2 versus 24 months; adjusted hazard ratio (aHR), 21.7; 95% confidence interval (CI), (6.4, 72.8). The boosted CART-derived threshold and its relevance to the final treatment outcome was comparable to the previously suggested target of AUC 0–24h /MIC (119) using MGIT MICs in a hollow fiber infection model. Based on the threshold from the present study, at a standard linezolid dose of 600 mg daily, PTA was simulated to achieve 100% at MGIT MICs of ≤ .25 mg which included the majority (81.1%) of isolates in the study. Conclusion: We validated an AUC 0–24h /MIC threshold which may serve as a target for dose adjustment to improve efficacy of linezolid in a bedaquiline-containing treatment. Linezolid exposures with the WHO-recommended dose (600 mg daily) was sufficient for all the M. tb isolates with MIC ≤ .25 mg/L." @default.
• W4313891762 created "2023-01-10" @default.
• W4313891762 creator A5004848467 @default.
• W4313891762 creator A5006645827 @default.
• W4313891762 creator A5022854001 @default.
• W4313891762 creator A5024502790 @default.
• W4313891762 creator A5030569559 @default.
• W4313891762 creator A5031491320 @default.
• W4313891762 creator A5033020599 @default.
• W4313891762 creator A5037967289 @default.
• W4313891762 creator A5081061481 @default.
• W4313891762 creator A5085060070 @default.
• W4313891762 date "2023-01-09" @default.
• W4313891762 modified "2023-10-16" @default.
• W4313891762 title "Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis" @default.
• W4313891762 cites W1558349821 @default.
• W4313891762 cites W1960472620 @default.
• W4313891762 cites W1963958149 @default.
• W4313891762 cites W2059014689 @default.
• W4313891762 cites W2107834145 @default.
• W4313891762 cites W2108960489 @default.
• W4313891762 cites W2119762586 @default.
• W4313891762 cites W2133590486 @default.
• W4313891762 cites W2168859775 @default.
• W4313891762 cites W2242834633 @default.
• W4313891762 cites W2516905116 @default.
• W4313891762 cites W2530722318 @default.
• W4313891762 cites W2531801166 @default.
• W4313891762 cites W2588431128 @default.
• W4313891762 cites W2604212592 @default.
• W4313891762 cites W2623986689 @default.
• W4313891762 cites W2891690058 @default.
• W4313891762 cites W2898390761 @default.
• W4313891762 cites W2899026086 @default.
• W4313891762 cites W2904326384 @default.
• W4313891762 cites W2909813694 @default.
• W4313891762 cites W2922735751 @default.
• W4313891762 cites W2972281770 @default.
• W4313891762 cites W3009599329 @default.
• W4313891762 cites W3048404415 @default.
• W4313891762 cites W3097743599 @default.
• W4313891762 cites W3113471566 @default.
• W4313891762 cites W3135702228 @default.
• W4313891762 cites W3209259794 @default.
• W4313891762 cites W4207024445 @default.
• W4313891762 cites W4308121155 @default.
• W4313891762 doi "https://doi.org/10.3389/fphar.2022.1032674" @default.
• W4313891762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36699070" @default.
• W4313891762 hasPublicationYear "2023" @default.
• W4313891762 type Work @default.
• W4313891762 citedByCount "0" @default.
• W4313891762 crossrefType "journal-article" @default.
• W4313891762 hasAuthorship W4313891762A5004848467 @default.
• W4313891762 hasAuthorship W4313891762A5006645827 @default.
• W4313891762 hasAuthorship W4313891762A5022854001 @default.
• W4313891762 hasAuthorship W4313891762A5024502790 @default.
• W4313891762 hasAuthorship W4313891762A5030569559 @default.
• W4313891762 hasAuthorship W4313891762A5031491320 @default.
• W4313891762 hasAuthorship W4313891762A5033020599 @default.
• W4313891762 hasAuthorship W4313891762A5037967289 @default.
• W4313891762 hasAuthorship W4313891762A5081061481 @default.
• W4313891762 hasAuthorship W4313891762A5085060070 @default.
• W4313891762 hasBestOaLocation W43138917621 @default.
• W4313891762 hasConcept C111113717 @default.
• W4313891762 hasConcept C112705442 @default.
• W4313891762 hasConcept C126322002 @default.
• W4313891762 hasConcept C142724271 @default.
• W4313891762 hasConcept C2778980435 @default.
• W4313891762 hasConcept C2779489039 @default.
• W4313891762 hasConcept C2781069245 @default.
• W4313891762 hasConcept C2781413609 @default.
• W4313891762 hasConcept C2781414143 @default.
• W4313891762 hasConcept C2908647359 @default.
• W4313891762 hasConcept C523546767 @default.
• W4313891762 hasConcept C54355233 @default.
• W4313891762 hasConcept C71924100 @default.
• W4313891762 hasConcept C72563966 @default.
• W4313891762 hasConcept C76318530 @default.
• W4313891762 hasConcept C86803240 @default.
• W4313891762 hasConcept C98274493 @default.
• W4313891762 hasConcept C99454951 @default.
• W4313891762 hasConceptScore W4313891762C111113717 @default.
• W4313891762 hasConceptScore W4313891762C112705442 @default.
• W4313891762 hasConceptScore W4313891762C126322002 @default.
• W4313891762 hasConceptScore W4313891762C142724271 @default.
• W4313891762 hasConceptScore W4313891762C2778980435 @default.
• W4313891762 hasConceptScore W4313891762C2779489039 @default.
• W4313891762 hasConceptScore W4313891762C2781069245 @default.
• W4313891762 hasConceptScore W4313891762C2781413609 @default.
• W4313891762 hasConceptScore W4313891762C2781414143 @default.
• W4313891762 hasConceptScore W4313891762C2908647359 @default.
• W4313891762 hasConceptScore W4313891762C523546767 @default.
• W4313891762 hasConceptScore W4313891762C54355233 @default.
• W4313891762 hasConceptScore W4313891762C71924100 @default.
• W4313891762 hasConceptScore W4313891762C72563966 @default.
• W4313891762 hasConceptScore W4313891762C76318530 @default.
• W4313891762 hasConceptScore W4313891762C86803240 @default.
• W4313891762 hasConceptScore W4313891762C98274493 @default.
• W4313891762 hasConceptScore W4313891762C99454951 @default.
• W4313891762 hasFunder F4320321001 @default.

• next